CARDIOVASCULAR RISK REDUCTION BY REVERSING ENDOTHELIAL DYSFUNCTION: ARBS, ACE INHIBITORS,  OR BOTH? EXPECTATIONS FROM THE ONTARGET  TRIAL PROGRAMME

Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors,  or both? Expectations from The ONTARGET  Trial Programme

Luis Miguel  Ruilope1, Josep Redón2, Roland Schmieder31Servicio de Nefrologia, Unidad de Hipertension Hospital, 12 de Octubre, Madrid, Spain; 2Department of Internal Medicine, Hospital Clinico University of Valencia, Valencia, Spain; 3Department of Nephrology and Hypertension, Friedrich-Alexander-Universitat, Erlangen-Nurnberg, GermanyA

read more




Benign and Borderline Phyllodes: Management and Follow-Up

Background: Phyllodes tumours of the breast are benign, borderline or malignant fibroepithelial lesions.They are uncommon and usually treated with surgical or radiological excision.The association with local recurrence has led to much debate over the extent of excision margins.It has traditionally followed that clinical surveillance for local recur

read more